Regeneron Pharmaceuticals, Inc. (REGN) Earnings History
Steady Earner35 years of earnings data (1991–2025) · Positive but moderate multi-year EPS trajectory
Loading earnings history...
Regeneron Pharmaceuticals, Inc. (REGN) Earnings Overview
As of June 22, 2026, Regeneron Pharmaceuticals, Inc. (REGN) reported trailing twelve-month net income of $4.42B, reflecting +8.2% year-over-year growth. The company earned $41.07 per diluted share over the past four quarters, with a net profit margin of 31.4%.
Looking at the long-term picture, REGN's 5-year EPS compound annual growth rate (CAGR) stands at +6.3%, showing solid earnings momentum. The company achieved its highest annual net income of $8.08B in fiscal 2021.
Regeneron Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 85.4%, operating margin of 24.9%, and net margin of 31.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including BIIB ($1.37B net income, 13.2% margin), VRTX ($4.34B net income, 32.7% margin), INCY ($1.43B net income, 25.0% margin), REGN has outperformed on profitability metrics. Compare REGN vs BIIB →
REGN Earnings vs Peers
Earnings metrics vs comparable public companies
REGN Historical Earnings Data (1991–2025)
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.50B | +2.1% | $3.58B | $41.48 | 31.4% | 24.9% |
| 2024 | $4.41B | +11.6% | $3.99B | $38.34 | 31.1% | 28.1% |
| 2023 | $3.95B | -8.9% | $4.35B | $34.77 | 30.1% | 33.2% |
| 2022 | $4.34B | -46.3% | $5.39B | $38.22 | 35.6% | 44.2% |
| 2021 | $8.08B | +129.9% | $8.95B | $71.97 | 50.2% | 55.7% |
| 2020 | $3.51B | +66.0% | $3.58B | $30.52 | 41.3% | 42.1% |
| 2019 | $2.12B | -13.4% | $2.21B | $18.46 | 32.3% | 33.7% |
| 2018 | $2.44B | +104.0% | $2.53B | $21.29 | 36.4% | 37.8% |
| 2017 | $1.20B | +33.8% | $2.08B | $10.34 | 20.4% | 35.4% |
| 2016 | $896M | +40.8% | $1.33B | $7.70 | 18.4% | 27.4% |
| 2015 | $636M | +82.7% | $1.25B | $5.52 | 15.5% | 30.5% |
| 2014 | $348M | -18.0% | $824M | $2.98 | 12.3% | 29.2% |
| 2013 | $424M | -43.4% | $743M | $3.72 | 20.2% | 35.3% |
| 2012 | $750M | +438.3% | $461M | $6.75 | 54.4% | 33.4% |
| 2011 | -$222M | -112.3% | -$205M | $-2.45 | -49.7% | -46.0% |
| 2010 | -$104M | -54.0% | -$97M | $-1.26 | -22.8% | -21.2% |
| 2009 | -$68M | +18.0% | -$74M | $-0.85 | -17.9% | -19.5% |
| 2008 | -$83M | +21.7% | -$90M | $-1.05 | -34.7% | -37.7% |
| 2007 | -$106M | -3.2% | -$114M | $-1.59 | -84.5% | -91.5% |
| 2006 | -$102M | -7.2% | -$107M | $-1.77 | -161.3% | -169.1% |
| 2005 | -$95M | -328.9% | -$124M | $-1.71 | -144.2% | -188.0% |
| 2004 | $42M | +138.8% | $6M | $0.74 | 24.0% | 3.2% |
| 2003 | -$107M | +13.6% | -$100M | $-2.13 | -186.9% | -173.9% |
| 2002 | -$124M | -63.3% | -$122M | $-2.83 | -565.7% | -554.6% |
| 2001 | -$76M | -228.1% | -$86M | $-1.81 | -346.7% | -389.9% |
| 2000 | -$23M | -0.5% | -$25M | $-0.66 | -39.2% | -42.6% |
| 1999 | -$23M | -168.6% | -$24M | $-0.73 | -67.0% | -69.0% |
| 1998 | -$9M | +25.9% | -$13M | $-0.28 | -22.5% | -32.7% |
| 1997 | -$12M | +64.2% | -$8M | $-0.40 | -35.0% | -22.7% |
| 1996 | -$32M | -37.9% | -$17M | $-1.32 | -134.4% | -71.8% |
| 1995 | -$24M | +23.5% | -$8M | $-1.19 | -85.8% | -27.7% |
| 1994 | -$31M | +23.1% | -$29M | $-1.62 | -132.3% | -125.9% |
| 1993 | -$40M | -108.9% | -$39M | $-2.41 | -376.4% | -366.0% |
| 1992 | -$19M | -324.4% | -$18M | $-1.24 | -166.1% | -159.1% |
| 1991 | -$5M | - | -$10M | $-0.29 | -61.6% | -131.5% |
Download Data
Export REGN earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into REGN consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
35+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
REGN — Frequently Asked Questions
Quick answers to the most common questions about buying REGN stock.
What is REGN earnings per share (EPS)?
REGN trailing twelve-month (TTM) diluted EPS is $41.07, reflecting +8.2% year-over-year growth. The 5-year EPS CAGR is +6.3%. Complete EPS history from 1991 to 2025 is available in the table on this page.
What is Regeneron Pharmaceuticals, Inc.'s net income?
Regeneron Pharmaceuticals, Inc. (REGN) trailing twelve-month net income is $4.4B as of 2025. Earnings grew +8.2% year-over-year. Regeneron Pharmaceuticals, Inc. has been profitable for 14 consecutive years.
Is REGN profitable?
Yes, REGN is profitable with a TTM net income of $4.4B and a net profit margin of +31.4%. Regeneron Pharmaceuticals, Inc. has generated profits for 14 consecutive years.
What is REGN's earnings growth rate?
REGN compound annual EPS growth rates (CAGR): 1-Year: +8.2%, 3-Year: +2.8%, 5-Year: +6.3%, 10-Year: +22.3%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1991 to 2025.
What are REGN's profit margins?
Regeneron Pharmaceuticals, Inc. net profit margin is +31.4%, operating margin is +24.9%, and gross margin is +85.4%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +14.9%.
Is REGN growing earnings?
REGN is growing earnings steadily. YoY EPS growth of +8.2% is consistent with the 5-year CAGR of +6.3%. TTM net income is $4.4B.
What was REGN's best earnings year?
Regeneron Pharmaceuticals, Inc.'s highest annual net income on record is $8.1B, achieved in fiscal year 2021. Earnings history on this page spans 1991 to 2025 and includes all annual and quarterly figures.
What were REGN's earnings last quarter?
REGN's most recent reported quarter was Q1 2026. Net income was $727M with diluted EPS of $6.75. For a full breakdown of all quarters, see the quarterly earnings table on this page.